The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Calcium Carbonate · CALCIUM CARBONATE 1250 mg/5mL · Suspension · Oral · Atlantic Biologicals Corps
NDC 17856-3117-03 · 5 mL in 1 CUP · OTC MONOGRAPH DRUG · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| PAI Holdings, LLC dba PAI Pharma | CALCIUM CARBONATE 1250 mg/5mL | Jul 15, 2026 | Sep 3, 2026 |
| Atlantic Biologicals Corps | CALCIUM CARBONATE 1250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Calcium Carbonate — NDC 17856-3117-03," retrieved September 3, 2026, https://drugdashboards.com/drug/17856311703.
Free to cite with attribution — see how the data is put together.